NeuroVive Pharmaceutical AB publishes 2019 Annual report
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the English version of the Annual report for 2019 is now available on the company’s website, www.neurovive.com.
Press releases
NeuroVive Pharmaceutical AB Year End Report January – December 2019
Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...
NeuroVive Pharmaceutical AB Interim Report January – September 2019
Continued progress in KL1333.
NeuroVive Pharmaceutical AB Interim Report January – June 2019
Focus on genetic mitochondrial diseases
NeuroVive Pharmaceutical AB Interim Report January – March 2019
First subjects enrolled in the KL1333 study
NeuroVive Pharmaceutical AB publishes 2018 Annual report
Lund, Sweden, 25 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company’s ...
NeuroVive Pharmaceutical AB Year End Report January – December 2018
Positioned for clinical progress
NeuroVive Pharmaceutical AB Interim report January – September 2018
KL1333 approved for phase I clinical trial
NeuroVive Pharmaceutical AB Interim report January – June 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio
NeuroVive Pharmaceutical AB Interim report January – March 2018
Successful rights issue
NeuroVive Pharmaceutical AB publishes 2017 Annual report
Lund, Sweden, 26 March, 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2017 is now available on the company's ...
NeuroVive Pharmaceutical AB Year End Report January – December 2017
Strong trend for mitochondrial disorder projects